Skip to content
Icon-linkedin Youtube
Search
Contact us
  • About EMQN
    • Organisation
    • Careers
    • News & Events
    • Sustainability statement
    • Accreditation and Quality
  • EQA Scheme Catalogue
  • About EQA Schemes
    • 2026 Registration
    • Samples Donation
    • Discounts for evolving economies
  • Our Assessors
    • How to apply
    • Assessor Vacancies
  • Resources
    • Best Practices
    • Webinars
    • Case Studies
    • Publications
  • Support
  • About EMQN
    • Organisation
    • Careers
    • News & Events
    • Sustainability statement
    • Accreditation and Quality
  • EQA Scheme Catalogue
  • About EQA Schemes
    • 2026 Registration
    • Samples Donation
    • Discounts for evolving economies
  • Our Assessors
    • How to apply
    • Assessor Vacancies
  • Resources
    • Best Practices
    • Webinars
    • Case Studies
    • Publications
  • Support
Become a member/ log in
Search
Contact us
Log in
Icon-linkedin Icon-x Youtube
  • About EMQN
    • Organisation
    • Careers
    • News & Events
    • Sustainability statement
    • Accreditation and Quality
  • EQA Scheme Catalogue
  • About EQA Schemes
    • 2026 Registration
    • Samples Donation
    • Discounts for evolving economies
  • Our Assessors
    • How to apply
    • Assessor Vacancies
  • Resources
    • Best Practices
    • Webinars
    • Case Studies
    • Publications
  • Support
  • About EMQN
    • Organisation
    • Careers
    • News & Events
    • Sustainability statement
    • Accreditation and Quality
  • EQA Scheme Catalogue
  • About EQA Schemes
    • 2026 Registration
    • Samples Donation
    • Discounts for evolving economies
  • Our Assessors
    • How to apply
    • Assessor Vacancies
  • Resources
    • Best Practices
    • Webinars
    • Case Studies
    • Publications
  • Support

Language: German

Pharmacogenetics (DPYD / UGT1A1 only)

DPYD and/or UGT1A1 pharmacogenetic testing for drug response and efficacy (Germline DNA).

Pharmacogenetics (panel testing)

Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).

Microsatellite Instability testing (MSI) [Tissue]

Microsatellite Instability testing testing (FFPE).

Ovarian, Breast, Prostate and Pancreatic Cancers (PARPi) [DNA, Germline]

BRCA1 and BRCA2 testing for Ovarian, Breast, prostate and pancreatic cancer (Germline DNA) in the context of PARP inhibitor prescription. This EQA is sponsored.

Prostate cancer (PARPi) [Plasma, cfDNA]

BRCA1 and BRCA2 testing in cfDNA (plasma) for Prostate Cancer in the context of PARP inhibitor prescription. This EQA is sponsored.

Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]

BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.

Next →

EMQN Office 

Third Floor, ICE Building, 3 Exchange Quay

Salford, M5 3ED

office@emqn.org 
+44 161 757 1591

Subscribe to our newsletter

Subscribe
Contact us for more information
Contact us
Click here for more information

Subscribe to our newsletter

Subscribe
Contact us for more information
Contact us

EMQN Office

Unit 4, Enterprise House
Pencroft Way
Manchester Science Park
Manchester
M15 6SE
UK

office@emqn.org
+44 161 757 1591

Click here for more information

Terms & Conditions | Privacy Policy 

©2026 EMQN. All rights reserved.